)
Visual
test
Vivani Medical
Vivani Medical (VANI) investor relations material
Vivani Medical Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Mar, 2026
Executive summary
Completed first-in-human LIBERATE-1 study and advanced NPM-139, a semaglutide implant, toward Phase 1 clinical trials with results expected by end of 2026.
Demonstrated >20% sham-adjusted weight loss for a full year in preclinical semaglutide implant studies.
Raised $41.5M in gross proceeds through financings, supporting operations into mid-2027.
Preparing for commercial-scale manufacturing and planning a Phase 1 study in Australia for NPM-139.
Financial highlights
Cash and equivalents totaled $16.2M as of December 31, 2025, down from $18.4M at year-end 2024.
Net loss for Q4 2025 was $6.6M, up from $6.1M in Q4 2024; full-year net loss was $26.6M, up from $23.5M in 2024.
Research and development expenses for 2025 were $18.1M, a 15% increase year-over-year.
General and administrative expenses for 2025 were $9.4M, a 6% increase year-over-year.
Other income, net, for 2025 was $0.9M, down from $1.2M in 2024.
Outlook and guidance
Phase 1 study for NPM-139 expected to begin mid-2026, with results anticipated by year-end 2026.
IND filing planned to support a Phase 2 dose-ranging study for NPM-139.
Exploring spin-off or IPO for Cortigent, with transition to an independent public company underway.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vivani Medical
- Long-acting GLP-1 implants promise improved adherence and outcomes in obesity care.VANI
Corporate presentation26 Mar 2026 - A once or twice-yearly GLP-1 implant targets adherence and access gaps in chronic disease care.VANI2025 ThinkEquity Conference3 Feb 2026
- Long-acting implant technology targets improved adherence and outcomes in obesity and diabetes.VANIH.C. Wainwright 26th Annual Global Investment Conference 202420 Jan 2026
- Long-acting GLP-1 implant targets improved adherence, with Phase I data expected by mid-2025.VANIMaxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026
- First-in-human trial of a six-month GLP-1 implant underway, with results expected mid-year.VANIEmerging Growth Virtual Conference 7810 Jan 2026
- Proprietary drug implants show promise for obesity and diabetes, with key data expected mid-year.VANIEmerging Growth Virtual Conference19 Dec 2025
- Semaglutide implant targets long-term adherence and tolerability in obesity care, with trials imminent.VANIEmerging Growth Conference 202517 Dec 2025
- Shareholders will vote on directors, auditor ratification, and executive pay, with board support for all.VANIProxy Filing2 Dec 2025
- Virtual 2025 meeting to vote on directors, auditor, and executive pay; strong governance in place.VANIProxy Filing2 Dec 2025
Next Vivani Medical earnings date
Q1 202612 May, 2026
Vivani Medical
Next Vivani Medical earnings date
Q1 202612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage